Ross James A, Mandenius Carl-Fredrik
Tissue Injury & Repair Group, Chancellor's Building, University of Edinburgh, Edinburgh, UK.
Division of Biophysics and Bioengineering, Department of Physics, Chemistry and Biology, Linköping University, Linköping, Sweden.
Methods Mol Biol. 2025;2924:1-14. doi: 10.1007/978-1-0716-4530-7_1.
The use of human-induced pluripotent cell lines in the differentiation of specific cell types and assay development has in recent years progressed significantly. In this introduction to the field, the rationale for using induced pluripotent stem cells in drug development is described and some of the advantages and drawbacks are discussed. The prospect of facilitating drug development by using stratified sources of cells from diverse patient groups and differentiating these to organ and tissue cells for their use in disease models, screening assays, and ADME testing is highlighted. The variety of methodologies and protocols presented in this volume provides a selected collection of experiences and practice. Here, these are discussed in a general perspective with references and comments to other similar protocols in the literature.
近年来,人类诱导多能细胞系在特定细胞类型的分化及检测方法开发中的应用取得了显著进展。在本领域介绍中,阐述了在药物开发中使用诱导多能干细胞的基本原理,并讨论了一些优缺点。强调了利用来自不同患者群体的分层细胞来源,并将这些细胞分化为器官和组织细胞以用于疾病模型、筛选检测和药物代谢动力学测试来促进药物开发的前景。本卷中介绍的各种方法和方案提供了一系列精选的经验和实践。在此,将从总体角度对这些内容进行讨论,并参考和评论文献中其他类似的方案。